Last updated: September 7, 2026
Capivasertib, marketed by AstraZeneca as Truqap, is an oral AKT inhibitor approved with fulvestrant for adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer carrying one or more PIK3CA, AKT1, or PTEN alterations. Its commercial opportunity depends on three factors: adoption after CDK4/6 inhibitor therapy, routine use of molecular testing, and competition from other targeted therapies such as inavolisib, alpelisib, elacestrant, and everolimus.
The drug has a differentiated biomarker strategy but entered a crowded post-endocrine-resistance market. AstraZeneca’s near-term objective is to establish capivasertib as a broad AKT-pathway therapy rather than a niche treatment limited to patients with a single mutation.
What is capivasertib and how does Truqap work?
Capivasertib is a selective small-molecule inhibitor of AKT1, AKT2, and AKT3. AKT is a central component of the PI3K-AKT-mTOR signaling pathway, which supports tumor-cell survival, proliferation, and endocrine-treatment resistance.
The U.S. Food and Drug Administration approved Truqap on November 16, 2023, in combination with fulvestrant for adults with HR-positive, HER2-negative advanced or metastatic breast cancer whose tumors have one or more qualifying PIK3CA, AKT1, or PTEN alterations after progression on at least one endocrine-based regimen in the metastatic setting or recurrence during or within 12 months of completing adjuvant therapy. [1]
The approved regimen is:
| Parameter |
Truqap regimen |
| Active ingredient |
Capivasertib |
| Brand |
Truqap |
| Partner therapy |
Fulvestrant |
| Dose |
400 mg orally twice daily |
| Schedule |
Four days on, three days off |
| FDA indication |
HR-positive, HER2-negative advanced or metastatic breast cancer |
| Biomarker requirement |
PIK3CA, AKT1, or PTEN alteration |
| Initial U.S. approval |
November 16, 2023 |
| Commercial company |
AstraZeneca |
The intermittent dosing schedule is intended to manage on-target toxicities, particularly diarrhea, rash, hyperglycemia, and stomatitis.
What clinical evidence supports capivasertib adoption?
The principal evidence is the CAPItello-291 Phase 3 trial, which randomized patients with HR-positive, HER2-negative advanced breast cancer to capivasertib plus fulvestrant or placebo plus fulvestrant.
In the overall population, median progression-free survival was 7.2 months with capivasertib plus fulvestrant versus 3.6 months with fulvestrant alone. In the subgroup with qualifying PIK3CA, AKT1, or PTEN alterations, median progression-free survival was 7.3 months versus 3.1 months. The hazard ratio for progression or death was 0.50 in the alteration-positive subgroup. [2]
The clinical value proposition is strongest in patients who:
- Have progressed on a CDK4/6 inhibitor and endocrine therapy.
- Have an AKT-pathway alteration.
- Need an oral targeted option without chemotherapy.
- Are not suitable for, or cannot tolerate, other pathway-directed treatments.
The main commercial limitation is that the trial also showed benefit in the overall population, while the U.S. label requires a qualifying biomarker alteration. That creates a testing and patient-identification barrier even though the underlying biology may be broader than the approved population.
How large is the capivasertib market opportunity?
The addressable market is the later-line HR-positive, HER2-negative metastatic breast cancer population, particularly patients previously treated with CDK4/6 inhibitors. This is a large segment, but the market is fragmented among several therapies with overlapping positioning.
A practical market funnel is:
| Market layer |
Commercial relevance |
| All metastatic HR-positive breast cancer |
Large disease pool, but most patients are not eligible for immediate capivasertib use |
| Patients progressing after CDK4/6 therapy |
Core treatment setting |
| Patients with PIK3CA, AKT1, or PTEN alterations |
U.S. label-defined population |
| Patients tested, medically suitable, and treated with fulvestrant |
Realistic near-term commercial pool |
| Earlier-line or combination use |
Future expansion opportunity |
AstraZeneca has not publicly framed Truqap as a blockbuster product on the scale of Tagrisso, Imfinzi, or Enhertu. Its commercial trajectory is more likely to resemble a targeted oncology franchise product with meaningful growth if testing becomes routine and additional indications are secured.
Revenue growth depends on several operational variables:
- Testing rates. PIK3CA testing is established, but AKT1 and PTEN testing is less standardized across community oncology practices.
- Line-of-therapy placement. Physicians must decide whether to use capivasertib before or after oral SERDs, PI3K inhibitors, antibody-drug conjugates, or chemotherapy.
- Fulvestrant use. The current label requires combination treatment, tying demand to fulvestrant prescribing and administration.
- Tolerability management. Diarrhea, rash, hyperglycemia, and dose interruptions can limit persistence.
- Competitive launches. Inavolisib and elacestrant are positioned in similar endocrine-resistant breast cancer populations.
AstraZeneca’s initial sales base was limited because the U.S. launch occurred late in 2023. The financial trajectory should therefore be assessed through prescription growth, geographic expansion, biomarker testing, and label expansion rather than early absolute revenue alone. AstraZeneca’s annual reporting identifies Truqap as a growth oncology asset but does not place it in the same revenue tier as its largest oncology products. [3]
What is the competitive landscape for capivasertib?
Capivasertib competes against both pathway inhibitors and broader endocrine-resistance therapies.
| Drug |
Company |
Target or mechanism |
Key positioning |
| Truqap, capivasertib |
AstraZeneca |
AKT1/2/3 inhibitor |
PIK3CA, AKT1, or PTEN-altered HR-positive/HER2-negative disease with fulvestrant |
| Itovebi, inavolisib |
Roche/Genentech |
PI3K alpha inhibitor |
PIK3CA-mutated HR-positive/HER2-negative disease with palbociclib and fulvestrant |
| Piqray, alpelisib |
Novartis |
PI3K alpha inhibitor |
PIK3CA-mutated HR-positive/HER2-negative disease with fulvestrant |
| Orserdu, elacestrant |
Menarini Group and Radius Health |
Oral selective estrogen receptor degrader |
ESR1-mutated, ER-positive/HER2-negative advanced or metastatic disease |
| Afinitor, everolimus |
Novartis |
mTOR inhibitor |
Endocrine-resistant HR-positive breast cancer with exemestane |
| Trodelvy, sacituzumab govitecan |
Gilead |
TROP-2 antibody-drug conjugate |
Later-line breast cancer, including endocrine-resistant disease |
| Chemotherapy |
Multiple companies |
Cytotoxic therapy |
Later-line fallback and high-burden disease |
How does capivasertib compare with inavolisib?
Inavolisib is the most important emerging targeted competitor in the PIK3CA-mutated segment. Its combination with palbociclib and fulvestrant is positioned earlier in treatment than capivasertib’s current U.S. label. If clinicians use inavolisib before capivasertib, Truqap could become a later-line option for patients who have already received a CDK4/6 inhibitor and a PI3K-directed regimen.
Capivasertib has a broader biomarker footprint because its label includes PIK3CA, AKT1, and PTEN alterations. Inavolisib has a narrower PIK3CA-mutated focus but may benefit from earlier-line use and a regimen designed around palbociclib.
How does capivasertib compare with alpelisib?
Alpelisib has established PIK3CA-directed use but is associated with hyperglycemia, rash, diarrhea, and treatment discontinuation. Capivasertib also produces metabolic and gastrointestinal toxicities, but the intermittent schedule and broader biomarker label may support differentiation.
The comparison will depend on real-world treatment persistence, biomarker prevalence, physician familiarity, and payer restrictions.
What regulatory exclusivity does capivasertib have?
Capivasertib received standard FDA approval rather than accelerated approval. The approval was based on clinical benefit demonstrated in CAPItello-291. The FDA label includes a companion diagnostic requirement for identifying PIK3CA, AKT1, and PTEN alterations. [1]
The five-year U.S. new chemical entity exclusivity period is expected to run from the November 16, 2023 approval date to November 2028, subject to statutory treatment of the active moiety and any applicable exclusivity adjustments. The principal U.S. commercial protection may extend beyond that date through patents, pediatric exclusivity, or additional listed claims.
The European Commission granted marketing authorization for Truqap in 2024 in combination with fulvestrant for the corresponding biomarker-defined population. European protection is governed by the EU’s eight-year data-exclusivity and two-year market-protection framework, with a possible one-year extension for a significant new therapeutic indication. [4]
What patents protect capivasertib?
Capivasertib is protected by a patent estate covering the active compound, related chemical structures, pharmaceutical compositions, and therapeutic use. AstraZeneca’s principal patent strategy is expected to rely on:
- Composition-of-matter claims covering capivasertib and related compounds.
- Salt, crystalline-form, and solid-state claims.
- Pharmaceutical-composition claims.
- Combination claims involving fulvestrant or endocrine therapy.
- Method-of-use claims for biomarker-selected breast cancer.
- Manufacturing and process claims.
The first U.S. generic-entry date is not determined solely by the five-year NCE period. It will depend on the expiration and enforceability of the relevant listed patents, any pediatric extension, and the outcome of potential Paragraph IV litigation.
The commercial importance of formulation and manufacturing patents is lower than the core compound patent unless those patents extend materially beyond composition-of-matter protection. Capivasertib is an oral small molecule, so it does not have the biologic-style manufacturing complexity or biosimilar exclusivity structure associated with monoclonal antibodies.
When does capivasertib lose exclusivity?
The earliest clear U.S. regulatory exclusivity milestone is November 2028, when five-year NCE exclusivity is expected to expire. That date does not necessarily permit immediate generic launch.
| Exclusivity element |
Relevance |
| FDA NCE exclusivity |
Expected to run through approximately November 2028 |
| Core compound patents |
May delay generic approval or launch beyond NCE expiry |
| Formulation patents |
Could provide additional protection if listed and enforceable |
| Method-of-use patents |
May restrict labeled use without necessarily blocking all generic sales |
| Pediatric exclusivity |
Could add six months if awarded |
| Paragraph IV litigation |
May trigger a 30-month stay for an ANDA applicant |
| Generic launch |
Could be at risk from 2028 onward, but timing depends on patent disputes |
No publicly prominent U.S. Paragraph IV challenge or settlement involving capivasertib had reshaped the commercial outlook through the early commercial period. The absence of a disclosed challenge does not remove future risk, particularly as the 2028 NCE milestone approaches.
Is capivasertib exposed to biosimilar risk?
No. Capivasertib is a chemically synthesized small molecule, not a biologic. It is exposed to conventional generic-drug competition through the Abbreviated New Drug Application pathway rather than biosimilar competition under the Public Health Service Act.
The main generic risks are:
- An authorized generic or first-filer launch after patent settlement.
- A Paragraph IV challenge to core compound or formulation patents.
- Narrow-label generic entry that avoids certain method-of-use claims.
- Price erosion after multiple generic entrants.
- Substitution pressure from generic fulvestrant and other low-cost endocrine partners.
What is the litigation and settlement outlook?
The key future litigation issue is likely to be ANDA litigation rather than infringement litigation over commercial use. A generic applicant could challenge listed patents by asserting invalidity, noninfringement, or unenforceability under Paragraph IV.
Potential settlement structures include:
- A licensed entry date before full patent expiry.
- A payment-free settlement with a delayed launch.
- An authorized-generic arrangement.
- Restrictions limited to specific indications or formulations.
Because capivasertib is still in the early commercial phase, the most important legal event is likely to be the first credible ANDA filing rather than a current high-profile dispute.
What are the main revenue risks and upside drivers?
Upside drivers
- Expansion into earlier-line HR-positive breast cancer.
- Use in patients with PTEN or AKT1 alterations, where treatment options are more limited.
- Combination studies with CDK4/6 inhibitors, oral SERDs, or other targeted agents.
- Increased adoption of comprehensive genomic testing.
- Geographic expansion across Europe and other major oncology markets.
- Demonstrated tolerability relative to PI3K-pathway alternatives.
Revenue risks
- Inavolisib capturing PIK3CA-mutated patients earlier.
- Elacestrant or other oral SERDs becoming preferred after CDK4/6 progression.
- Low testing rates for AKT1 and PTEN alterations.
- Dose reductions caused by diarrhea, rash, hyperglycemia, or stomatitis.
- Fulvestrant administration burden and competition from oral endocrine combinations.
- Payer controls that require prior treatment with cheaper endocrine agents.
- Generic erosion beginning near or after the 2028 U.S. exclusivity milestone.
How strong is the capivasertib patent and commercial estate?
The estate is commercially meaningful but not structurally difficult to replicate in the way that a biologic manufacturing platform can be. The strongest protection is likely the active-compound patent family and any surviving patent-term extensions. Formulation, method-of-use, and manufacturing patents can supplement that protection but may be easier for generic applicants to design around.
Commercial strength is therefore higher before 2028 and increasingly dependent on patent prosecution, litigation outcomes, and lifecycle management after that date. AstraZeneca’s best defense against future generic erosion is to build broad physician adoption, secure additional indications, and establish combination regimens that remain clinically differentiated.
Key Takeaways
- Truqap is an FDA-approved oral AKT inhibitor for biomarker-defined HR-positive, HER2-negative advanced or metastatic breast cancer.
- Its core evidence comes from CAPItello-291, which showed a meaningful progression-free-survival benefit with fulvestrant.
- The commercial opportunity is concentrated in patients who progress after CDK4/6 inhibitor therapy.
- Inavolisib is the most important emerging competitor, particularly in PIK3CA-mutated disease.
- The U.S. five-year NCE exclusivity milestone is expected in November 2028.
- Capivasertib faces generic, not biosimilar, competition.
- Long-term revenue depends on biomarker testing, earlier-line expansion, tolerability, and successful differentiation from PI3K inhibitors and oral SERDs.
- The patent estate is meaningful but will require active lifecycle management to delay post-2028 generic entry.
FAQs
Is capivasertib a chemotherapy drug?
No. Capivasertib is an oral targeted AKT inhibitor. It is used with fulvestrant and does not operate as a conventional cytotoxic chemotherapy.
Which biomarkers are required for Truqap in the United States?
The FDA-approved use requires a tumor alteration in PIK3CA, AKT1, or PTEN. Testing is performed with an FDA-approved or otherwise appropriately validated diagnostic method.
Can capivasertib be used with an aromatase inhibitor?
The current U.S. approval is with fulvestrant. Use with an aromatase inhibitor would require supporting clinical evidence and an applicable regulatory basis.
What is the main adverse-event concern with capivasertib?
Diarrhea is a major treatment-related adverse event. Rash, hyperglycemia, nausea, stomatitis, and dose interruptions are also important in treatment management.
Will generic capivasertib launch in 2028?
Generic filing or launch may become possible after the expected November 2028 NCE-exclusivity milestone, but actual launch timing will depend on listed patents, Paragraph IV litigation, settlements, pediatric exclusivity, and regulatory approval.
References
-
U.S. Food and Drug Administration. (2023). Truqap (capivasertib) prescribing information. FDA.
-
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortés, J., Gomez Moreno, H. L., et al. (2023). Capivasertib in hormone receptor-positive advanced breast cancer. The New England Journal of Medicine, 388(22), 2058-2070.
-
AstraZeneca PLC. (2024). Annual report and form 20-F 2023. AstraZeneca.
-
European Medicines Agency. (2024). Truqap: EPAR product information. EMA.
